darusentan (HMR-4005) / Gilead  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
darusentan (HMR-4005) / Gilead
NCT00330369 / 2006-001898-25: DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

Completed
3
352
US, Canada, Europe, RoW
Darusentan, LU 135252, Darusentan Placebo
Gilead Sciences
Hypertension
01/09
01/09
NCT00389779: DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

Completed
3
849
US, Europe, RoW
Darusentan, LU 135252, Guanfacine, Darusentan Placebo
Gilead Sciences
Hypertension
08/09
08/09
2006-003548-42: DORADO-AC-EX – A Double-Blind, Active-Controlled, Long-Term Safety Extension Study to the Phase 3 DORADO-AC Study (Protocol DAR-312) of Darusentan in Resistant HypertensionA Double-Blind, Active-Controlled, Long-Term Safety Extension Study of Optimized Doses of Darusentan in Subjects with Resistant Hypertension Despite Receiving Combination Therapy with Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine (Protocol DAR-312-E)

Completed
3
770
Europe
Darusentan, Estulic, LU 135252 or GS-9377, Capsule*, Estulic
Gilead Sciences, Inc.
Resistant hypertension
 
 
NCT00353574 / 2006-001899-20: DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension

Terminated
3
282
US, Canada, Europe, RoW
Darusentan
Gilead Sciences
Hypertension
02/10
04/10
NCT00389675: DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension

Terminated
3
661
US, RoW
Darusentan, LU 135252, Guanfacine
Gilead Sciences
Hypertension
02/10
05/10

Download Options